Michelle Lima de Carvalho Silva

Michelle Lima de Carvalho Silva

Auto-generated profile, based on publicly available information

Michelle Lima de Carvalho Silva

Faculdade Pernambucana de Saúde (FPS), Recife, PE, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2024 in Clinical Obesity
Verified
Journal Article
Closed access
GSGabrielle Ribeiro Sena
Gabrielle Ribeiro Sena
TLTiago Pessoa Ferreira de Lima
Tiago Pessoa Ferreira de Lima
MSMichelle Lima de Carvalho Silva
Michelle Lima de Carvalho Silva
PSPaloma Gomes Tavares Sette
Paloma Gomes Tavares Sette
GCGabriela Carla dos Santos Costa
Gabriela Carla dos Santos Costa
GCGuilherme Jorge Costa
Guilherme Jorge Costa

28 February 2026 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
ALAldicléya Lima Luz
Aldicléya Lima Luz
Elcio LealElcio Leal
Elcio Leal
KLKledoaldo Lima
Kledoaldo Lima
MSMikhael Morais de Souza
Mikhael Morais de Souza
MSMichelle Lima de Carvalho Silva
Michelle Lima de Carvalho Silva
HMHeloísa Ramos Lacerda de Melo
Heloísa Ramos Lacerda de Melo
Antiretroviral drug resistance poses a challenge to therapy efficacy. Although Integrase Strand Transfer Inhibitors (INSTIs) have a high genetic barrier to resistance, few studies in Brazil have focused on INSTI resistance. This study aimed to assess HIV mutations associated with INSTI resistance in vertically infected children in Maranhão and Pernambuco, Brazil. We conducted a retrospective analysis of antiretroviral resistance profiles in paediatric patients with virological failure receiving care through the Brazilian Unified Health System. Data on viral load, CD4+/CD8+ T-cell counts, and medication dispensing were obtained from Ministry of Health databases (SISGENO, SISCEL, and SICLOM). HIV-1 integrase sequences were analysed. Phylogenetic analysis (IQ-TREE) was used to identify subtypes and recombinants. Resistance-associated mutations were determined using the Stanford HIV Drug Resistance Database. Thirty-one paediatric patients (median age = 12-years) were included. Mean CD4+ count was 999 cells/mm³, and median viral load was 19,235 copies/mL. Subtype B and INSTI resistance mutations were detected in 74.5 % and 64.5 % of patients, respectively. High resistance rates to raltegravir (70.9 %) were observed, highlighting the importance of genotypic monitoring. A high frequency of INSTI resistance-associated mutations was identified, indicating the need for continued surveillance in this population.

31 August 2022 in Brazilian Journal of Development
Verified
Journal Article
Open access
PTPaula Cely da Silva Torres
Paula Cely da Silva Torres
FAFelipe Fonseca Sena de Azevedo
Felipe Fonseca Sena de Azevedo
MSMichelle Lima de Carvalho Silva
Michelle Lima de Carvalho Silva
RARafaella Mores Artifon
Rafaella Mores Artifon
IDIsabela Nicolai Nassif Diniz
Isabela Nicolai Nassif Diniz
JNJoseane Elizabete Nunes
Joseane Elizabete Nunes